Keynote Speakers Announced for SBC Open Innovation Summit Registration Now Open

Published: Aug 20, 2012

Stevenage, UK, August 20 2012 – Keynote speakers for 'Open Innovation in Action', taking place on November 15 2012 at Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, have been announced. Patrick Vallance, President, Pharmaceuticals R&D at GlaxoSmithKline, and Stefan Lindegaard, open innovation expert and author, will be providing their insights at the conference, which is SBC's inaugural open innovation summit. Registration is now open1.

In his role as President, Pharmaceuticals R&D at GSK, Patrick ensures that the company maintains a flow of potential new medicines through the R&D pipeline from early discovery through to approval. Since joining from University College London, where he led the Division of Medicine, he has transformed GSK’s discovery engine. Stefan Lindegaard2 is a leading consultant and adviser to companies on open innovation and intrapreneurship. He has worked with a variety of companies, from Bang & Olufsen and Lego to Novo Nordisk, and is the author of two highly rated books on open innovation, The Open Innovation Revolution, and Making Open Innovation Work.

Other speakers include Martin Leblanc, President and CEO of Caprion Proteomics, Dr John Anson, Vice President at Oxford Gene Technology Biomarker Discovery and Dr John Bell, Vice President at Philips Research. With the summit focusing on making open innovation work in practice, these speakers and others will discuss using this emerging tool to boost productivity and competitiveness, a key issue for the global life sciences sector.

'We are delighted to have attracted keynote speakers of such high calibre to SBC's Open Innovation Summit' said Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. 'With these and many other fascinating presentations, and an interactive approach throughout the day, we expect attendees to make new and interesting connections to help them develop their businesses further.'

1For more information and registration, go to

2 For more information please go to

Join the open innovation debate at SBC:

LinkedIn - Stevenage Bioscience Catalyst Open Innovation Group

twitter - @SteBioCat

For more information, please contact:

Stevenage Bioscience Catalyst

Martino Picardo, CEO +44 (0)1438 906906

Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage drug discovery and development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility is expected to house a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to

About Open Innovation

Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and expertise. OI is characterised by highly effective use of connections and networks to exchange knowledge and ideas, external partners being involved at all stages of product development, equitable win-win business relationships, and new business models to maximise the value of intellectual property and other assets. Examples in various sectors have shown that the benefits of OI include reduced time to market for new products and services, access to new markets, improved innovation success rates and increased profits. SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs with an active network consisting of GlaxoSmithKline and its other stakeholders, academia, charities, other businesses and funding bodies. The term ‘Open Innovation’ and related research into its practice have been developed extensively by Professor Henry Chesbrough, Executive Director of the Program in Open Innovation at the University of California, Berkeley (

About GlaxoSmithKline

GSK aims to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world. Every hour we spend more than £300,000 (US$562,000) in our search for new medicines that can make a difference to patients.We are one of the pharmaceutical industry leaders, with an estimated seven per cent of the world's pharmaceutical market and one of the few companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs.

About the Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

About the Department for Business, Innovation and Skills

The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS - Investing in our future.

About the Technology Strategy Board

The Technology Strategy Board works to drive economic growth by making the UK a global leader in innovation. Established by the government, the Technology Strategy Board helps business to innovate faster and more effectively than would otherwise be possible. It uses its expertise, connections and funding to enable collaborations and partnerships between businesses, researchers and government, and to help business to create innovative products and services which will meet market needs, tackle the challenges of our time and build the economy of tomorrow.

About EEDA

EEDA's mission was to improve the economy of the East of England through helping businesses prosper, supporting people to be the best they can and breathing new life into places. Working with others it helped improve the lives of thousands of people with investments that will continue to have an impact for decades to come. EEDA worked across the six counties of Bedfordshire, Cambridgeshire, Essex, Hertfordshire, Norfolk and Suffolk , and unitary authorities of Central Bedfordshire, Bedford , Luton, Peterborough , Southend-on-Sea and Thurrock. In the Emergency Budget of 22 June 2010, the government confirmed its intention to abolish all regional development agencies and replace them with Local Enterprise Partnerships. EEDA closed in March 2012.

Emma Palmer Foster

Strategic Communications Consultant

Stevenage Bioscience Catalyst

m: +44 (0) 7880 787185


Stevenage Bioscience Catalyst

Gunnels Wood Road


Hertfordshire SG1 2FX

Back to news